Cargando…

Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group

PURPOSE: To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. PATIENTS AND METHODS: Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Abreu, Diego, Carvalhal, Gustavo, Gueglio, Guillermo, Tobia, Ignacio, Garcia, Patricio, Zuñiga, Alvaro, Meza, Luis, Bengió, Rubén, Scorticati, Carlos, Castillejos, Ricardo, Rodriguez, Francisco, Autran, Ana María, Gonzales, Carmen, Gadu, Jose, Nolazco, Alejandro, Ameri, Carlos, Zampolli, Hamilton, Langenhin, Raúl, Muguruza, Diego, Machado, Marcos Tobías, Mingote, Pablo, Yandian, Juan, Clavijo, Jorge, Nogueira, Lucas, Clark, Omar, Secin, Fernando, Rovegno, Agustín, Vilas, Ana, Barrios, Enrique, Decia, Ricardo, Guimarães, Gustavo, Glina, Sidney, Pal, Sumanta K., Rodriguez, Oscar, Palou, Joan, Spiess, Philippe, Lara, Primo N., Linehan, W. Marston, Pastore, Antonio Luigi, Zequi, Stenio C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162501/
https://www.ncbi.nlm.nih.gov/pubmed/33974442
http://dx.doi.org/10.1200/GO.20.00621
_version_ 1783700727054467072
author Abreu, Diego
Carvalhal, Gustavo
Gueglio, Guillermo
Tobia, Ignacio
Garcia, Patricio
Zuñiga, Alvaro
Meza, Luis
Bengió, Rubén
Scorticati, Carlos
Castillejos, Ricardo
Rodriguez, Francisco
Autran, Ana María
Gonzales, Carmen
Gadu, Jose
Nolazco, Alejandro
Ameri, Carlos
Zampolli, Hamilton
Langenhin, Raúl
Muguruza, Diego
Machado, Marcos Tobías
Mingote, Pablo
Yandian, Juan
Clavijo, Jorge
Nogueira, Lucas
Clark, Omar
Secin, Fernando
Rovegno, Agustín
Vilas, Ana
Barrios, Enrique
Decia, Ricardo
Guimarães, Gustavo
Glina, Sidney
Pal, Sumanta K.
Rodriguez, Oscar
Palou, Joan
Spiess, Philippe
Lara, Primo N.
Linehan, W. Marston
Pastore, Antonio Luigi
Zequi, Stenio C.
author_facet Abreu, Diego
Carvalhal, Gustavo
Gueglio, Guillermo
Tobia, Ignacio
Garcia, Patricio
Zuñiga, Alvaro
Meza, Luis
Bengió, Rubén
Scorticati, Carlos
Castillejos, Ricardo
Rodriguez, Francisco
Autran, Ana María
Gonzales, Carmen
Gadu, Jose
Nolazco, Alejandro
Ameri, Carlos
Zampolli, Hamilton
Langenhin, Raúl
Muguruza, Diego
Machado, Marcos Tobías
Mingote, Pablo
Yandian, Juan
Clavijo, Jorge
Nogueira, Lucas
Clark, Omar
Secin, Fernando
Rovegno, Agustín
Vilas, Ana
Barrios, Enrique
Decia, Ricardo
Guimarães, Gustavo
Glina, Sidney
Pal, Sumanta K.
Rodriguez, Oscar
Palou, Joan
Spiess, Philippe
Lara, Primo N.
Linehan, W. Marston
Pastore, Antonio Luigi
Zequi, Stenio C.
author_sort Abreu, Diego
collection PubMed
description PURPOSE: To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. PATIENTS AND METHODS: Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation. Relationships between clinical and pathological parameters and treatment-related outcomes were analyzed by Cox regression and the log-rank method. RESULTS: Of 530 patients, 184 (90.6%) had died of renal cell carcinoma. The median OS of the entire cohort was 24 months. American Society of Anesthesiology classification 3-4 (hazard ratio [HR]: 1.64), perirenal fat invasion (HR: 2.02), and ≥ 2 metastatic organ sites (HR: 2.19) were independent prognostic factors for 5-year OS in multivariable analyses. We created a risk group stratification with these variables: no adverse risk factors (favorable group), median OS not reached; one adverse factor (intermediate group), median OS 33 months (HR: 2.04); and two or three adverse factors (poor risk group), median OS 14 months (HR: 3.58). CONCLUSION: Our study defines novel prognostic factors that are relevant to a Latin American cohort. With external validation, these easily discerned clinical variables can be used to offer prognostic information across low- and middle-income countries.
format Online
Article
Text
id pubmed-8162501
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-81625012021-06-01 Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group Abreu, Diego Carvalhal, Gustavo Gueglio, Guillermo Tobia, Ignacio Garcia, Patricio Zuñiga, Alvaro Meza, Luis Bengió, Rubén Scorticati, Carlos Castillejos, Ricardo Rodriguez, Francisco Autran, Ana María Gonzales, Carmen Gadu, Jose Nolazco, Alejandro Ameri, Carlos Zampolli, Hamilton Langenhin, Raúl Muguruza, Diego Machado, Marcos Tobías Mingote, Pablo Yandian, Juan Clavijo, Jorge Nogueira, Lucas Clark, Omar Secin, Fernando Rovegno, Agustín Vilas, Ana Barrios, Enrique Decia, Ricardo Guimarães, Gustavo Glina, Sidney Pal, Sumanta K. Rodriguez, Oscar Palou, Joan Spiess, Philippe Lara, Primo N. Linehan, W. Marston Pastore, Antonio Luigi Zequi, Stenio C. JCO Glob Oncol ORIGINAL REPORTS PURPOSE: To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. PATIENTS AND METHODS: Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation. Relationships between clinical and pathological parameters and treatment-related outcomes were analyzed by Cox regression and the log-rank method. RESULTS: Of 530 patients, 184 (90.6%) had died of renal cell carcinoma. The median OS of the entire cohort was 24 months. American Society of Anesthesiology classification 3-4 (hazard ratio [HR]: 1.64), perirenal fat invasion (HR: 2.02), and ≥ 2 metastatic organ sites (HR: 2.19) were independent prognostic factors for 5-year OS in multivariable analyses. We created a risk group stratification with these variables: no adverse risk factors (favorable group), median OS not reached; one adverse factor (intermediate group), median OS 33 months (HR: 2.04); and two or three adverse factors (poor risk group), median OS 14 months (HR: 3.58). CONCLUSION: Our study defines novel prognostic factors that are relevant to a Latin American cohort. With external validation, these easily discerned clinical variables can be used to offer prognostic information across low- and middle-income countries. Wolters Kluwer Health 2021-05-11 /pmc/articles/PMC8162501/ /pubmed/33974442 http://dx.doi.org/10.1200/GO.20.00621 Text en © 2021 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle ORIGINAL REPORTS
Abreu, Diego
Carvalhal, Gustavo
Gueglio, Guillermo
Tobia, Ignacio
Garcia, Patricio
Zuñiga, Alvaro
Meza, Luis
Bengió, Rubén
Scorticati, Carlos
Castillejos, Ricardo
Rodriguez, Francisco
Autran, Ana María
Gonzales, Carmen
Gadu, Jose
Nolazco, Alejandro
Ameri, Carlos
Zampolli, Hamilton
Langenhin, Raúl
Muguruza, Diego
Machado, Marcos Tobías
Mingote, Pablo
Yandian, Juan
Clavijo, Jorge
Nogueira, Lucas
Clark, Omar
Secin, Fernando
Rovegno, Agustín
Vilas, Ana
Barrios, Enrique
Decia, Ricardo
Guimarães, Gustavo
Glina, Sidney
Pal, Sumanta K.
Rodriguez, Oscar
Palou, Joan
Spiess, Philippe
Lara, Primo N.
Linehan, W. Marston
Pastore, Antonio Luigi
Zequi, Stenio C.
Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group
title Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group
title_full Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group
title_fullStr Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group
title_full_unstemmed Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group
title_short Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group
title_sort prognostic factors in de novo metastatic renal cell carcinoma: a report from the latin american renal cancer group
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162501/
https://www.ncbi.nlm.nih.gov/pubmed/33974442
http://dx.doi.org/10.1200/GO.20.00621
work_keys_str_mv AT abreudiego prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT carvalhalgustavo prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT gueglioguillermo prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT tobiaignacio prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT garciapatricio prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT zunigaalvaro prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT mezaluis prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT bengioruben prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT scorticaticarlos prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT castillejosricardo prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT rodriguezfrancisco prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT autrananamaria prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT gonzalescarmen prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT gadujose prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT nolazcoalejandro prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT americarlos prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT zampollihamilton prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT langenhinraul prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT muguruzadiego prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT machadomarcostobias prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT mingotepablo prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT yandianjuan prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT clavijojorge prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT nogueiralucas prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT clarkomar prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT secinfernando prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT rovegnoagustin prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT vilasana prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT barriosenrique prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT deciaricardo prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT guimaraesgustavo prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT glinasidney prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT palsumantak prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT rodriguezoscar prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT paloujoan prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT spiessphilippe prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT laraprimon prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT linehanwmarston prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT pastoreantonioluigi prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup
AT zequistenioc prognosticfactorsindenovometastaticrenalcellcarcinomaareportfromthelatinamericanrenalcancergroup